Does the CYP1B1 rs1056836 GG genotype increase 4-hydroxylation and estrogen turnover?

The CYP1B1 rs1056836 (Val432Leu) polymorphism, specifically the GG genotype, is a well-characterized genetic variant that significantly alters the metabolic profile of estrogens. Research indicates that this variant shifts the enzymatic preference of CYP1B1, a key enzyme in extrahepatic estrogen metabolism, toward specific pathways that influence both systemic hormone levels and tissue-specific environments.

Clinical and metabolic evidence

• Enzymatic Activity and Substrate Preference: The GG genotype (coding for Valine at position 432 in many nomenclatures) is associated with higher catalytic efficiency for the 4-hydroxylation of estradiol compared to the Leu allele. This results in an elevated 4-OHE:2-OHE ratio, a metabolic shift often studied in the context of hormone-dependent tissues.
• Estrogen Turnover: Clinical data from nipple aspirate fluid and urinary metabolite studies suggest that the GG genotype facilitates faster metabolism of active estrogens. For example, individuals with the G allele have been shown to have lower estradiol concentrations and higher levels of catechol estrogen metabolites, indicating a phenotype of accelerated catabolism.
• Clinical Implications: In postmenopausal populations, this increased turnover and subsequent lower circulating estradiol have been linked to secondary physiological effects, such as reduced bone mineral density, reflecting the systemic impact of rapid estrogen clearance.

Mechanistic explanations

• 4-Hydroxylation Pathway: CYP1B1 primarily converts estrone and estradiol into 4-hydroxycatechol estrogens (4-OHE1 and 4-OHE2). The rs1056836 variant modifies the enzyme's active site or stability, specifically enhancing its ability to catalyze this 4-hydroxylation reaction.
• Oxidative Stress: Interestingly, while the G variant (Val432) increases catalytic efficiency toward 4-hydroxylation, it has also been associated with higher production of reactive oxygen species (ROS) in some experimental models, adding a secondary layer of biological impact beyond simple hormone clearance.
• Genotoxic Metabolites: The 4-hydroxy metabolites produced preferentially by this variant are more reactive and potentially genotoxic than the 2-hydroxy metabolites primarily produced by the liver enzyme CYP1A1. This mechanistic shift is the primary reason the GG genotype is studied for its role in estrogen-sensitive health outcomes.

Bottom line

The CYP1B1 rs1056836 GG genotype significantly enhances the 4-hydroxylation of estrogens and increases overall estrogen turnover. This leads to lower levels of active estradiol and a higher concentration of potentially genotoxic 4-hydroxy metabolites. For a 57-year-old female, this genotype suggests a metabolic profile characterized by rapid estrogen clearance and a shift toward the 4-hydroxylation pathway.